Search results for: life sciences & biotech

Key considerations when patenting microbiome inventions in Europe

In the latest article in our series, we outline the key considerations for innovators and applicants when patenting microbiome-related technologies in Europe....

Key considerations when patenting PROTACs in Europe

In this article, we outline the key considerations for innovators and applicants when patenting PROTACs in Europe....

Key considerations when patenting CRISPR-based therapeutics in Europe

In this article, we set out the key aspects for innovators and applicants to consider when patenting gene editors in Europe....

Innovation in the agri-tech space: How hard does the “essentially biological process” exclusion bite?

We examine why it is crucial for agri-tech companies to have awareness of the ''essentially biological process'' exclusion and when alternatives to patent protection should be considered....

Key considerations when patenting gene editors in Europe

We set out the key things for innovators and applicants to consider when patenting gene editors in Europe....

Key considerations when patenting chimeric antigen receptor technologies in Europe

We explore the therapeutic indications addressed by Chimeric Antigen Receptors (CARs) and CAR T-cell therapy and consider patent protection at the EPO...

Venture capital and intellectual property: Insights from the UK market

The UK’s venture capital (VC) landscape is undergoing a transformative shift, as recent trends and investment strategies highlight the critical role of intellectual property (IP) in securing funding...

From Code to Cure: DNA’s Contribution to Novel Medical Strategies

This year, National DNA Day will be celebrated on 25 April 2024, commemorating Watson and Crick’s publication of the double helix structure of DNA on the same day in 1953 [1] and the imminent comple...

Partnership News

We are delighted to announce that Ross Cummings and Ian Jones have joined the Partnership. Ross Cummings joined GJE in 2017, having previously worked at another top tier firm of patent and trade mark ...